🎉 M&A multiples are live!
Check it out!

Macrogenics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Macrogenics and similar public comparables like Pharming, Galapagos, and Vivoryon Therapeutics.

Macrogenics Overview

About Macrogenics

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.


Founded

2000

HQ

United States of America
Employees

341

Website

macrogenics.com

Financials

LTM Revenue $125M

LTM EBITDA n/a

EV

-$84.1M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Macrogenics Financials

Macrogenics has a last 12-month revenue of $125M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Macrogenics achieved revenue of $148M and an EBITDA of -$57.4M.

Macrogenics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Macrogenics valuation multiples based on analyst estimates

Macrogenics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $57.2M $148M XXX XXX XXX
Gross Profit $143M $49.0M XXX XXX XXX
Gross Margin 249% 33% XXX XXX XXX
EBITDA $2.0M -$57.4M XXX XXX XXX
EBITDA Margin 4% -39% XXX XXX XXX
Net Profit -$120M -$9.1M XXX XXX XXX
Net Margin -209% -6% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Macrogenics Stock Performance

As of April 15, 2025, Macrogenics's stock price is $1.

Macrogenics has current market cap of $80.1M, and EV of -$84.1M.

See Macrogenics trading valuation data

Macrogenics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$84.1M $80.1M XXX XXX XXX XXX $-1.50

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Macrogenics Valuation Multiples

As of April 15, 2025, Macrogenics has market cap of $80.1M and EV of -$84.1M.

Macrogenics's trades at -0.7x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Macrogenics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Macrogenics and 10K+ public comps

Macrogenics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$84.1M XXX XXX XXX
EV/Revenue -0.6x XXX XXX XXX
EV/EBITDA 1.5x XXX XXX XXX
P/E -1.2x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 1.2x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Macrogenics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Macrogenics Valuation Multiples

Macrogenics's NTM/LTM revenue growth is -45%

Macrogenics's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.7M for the same period.

Over next 12 months, Macrogenics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Macrogenics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Macrogenics and other 10K+ public comps

Macrogenics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 159% XXX XXX XXX XXX
EBITDA Margin -39% XXX XXX XXX XXX
EBITDA Growth -2944% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -83% XXX XXX XXX XXX
Revenue per Employee $0.4M XXX XXX XXX XXX
Opex per Employee $0.7M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 119% XXX XXX XXX XXX
Opex to Revenue 166% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Macrogenics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Macrogenics M&A and Investment Activity

Macrogenics acquired  XXX companies to date.

Last acquisition by Macrogenics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Macrogenics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Macrogenics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Macrogenics

When was Macrogenics founded? Macrogenics was founded in 2000.
Where is Macrogenics headquartered? Macrogenics is headquartered in United States of America.
How many employees does Macrogenics have? As of today, Macrogenics has 341 employees.
Who is the CEO of Macrogenics? Macrogenics's CEO is Dr. Scott Koenig, M.D.,PhD.
Is Macrogenics publicy listed? Yes, Macrogenics is a public company listed on NAS.
What is the stock symbol of Macrogenics? Macrogenics trades under MGNX ticker.
When did Macrogenics go public? Macrogenics went public in 2013.
Who are competitors of Macrogenics? Similar companies to Macrogenics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Macrogenics? Macrogenics's current market cap is $80.1M
What is the current revenue of Macrogenics? Macrogenics's last 12-month revenue is $125M.
What is the current EV/Revenue multiple of Macrogenics? Current revenue multiple of Macrogenics is -0.7x.
What is the current revenue growth of Macrogenics? Macrogenics revenue growth between 2023 and 2024 was 159%.
Is Macrogenics profitable? Yes, Macrogenics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.